Chembio Diagnostics Inc: Diferență între versiuni
The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Chembio Diagnostics Inc listata cu simbolul US.CEMI ==Descriere companie== Chembio Diagnostics, Inc. (www.chembio.com) develops, manufactures and commercializes point-of-care tests for the detection and diagnosis of infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Its DPP technology offers range of market applications beyond infectious disease. Its product portfolio is based upon its DPP technolo...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Chembio Diagnostics, Inc. (www.chembio.com) develops, manufactures and commercializes point-of-care tests for the detection and diagnosis of infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Its DPP technology offers range of market applications beyond infectious disease. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in approximately 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases, cardiac markers, cholesterol and lipids, pregnancy and fertility, and drugs of abuse. It targets rapid diagnostic test solutions for infectious diseases, including respiratory diseases, sexually transmitted diseases, gastroenterology and insect-vector diseases. The Company sells its products under the DPP, STAT PAK, SURE CHECK and STAT-VIEW trademarks. | Chembio Diagnostics, Inc. (www.chembio.com) develops, manufactures and commercializes point-of-care tests for the detection and diagnosis of infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Its DPP technology offers range of market applications beyond infectious disease. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in approximately 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the rapid diagnostic [[test]] market, which includes infectious diseases, cardiac markers, cholesterol and lipids, pregnancy and fertility, and drugs of abuse. It targets rapid diagnostic test solutions for infectious diseases, including respiratory diseases, sexually transmitted diseases, gastroenterology and insect-vector diseases. The Company sells its products under the DPP, STAT PAK, SURE CHECK and STAT-VIEW trademarks. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||